Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 41 matching trials from the live ClinicalTrials.gov search.
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Neurodevelopmental Outcomes in Craniosynostosis Repair

NCT04072783
Conditions
Craniosynostoses
Interventions
MRI,DTI, functional MRI
Diagnostic Test
Lead sponsor
University of Arkansas
Other
Eligibility
Up to 4 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Little Rock, Arkansas
Completed Not applicable Interventional Accepts healthy volunteers Results available

MRI for Non-invasive Evaluation of Brain Stress

NCT01898650
Conditions
Craniosynostosis
Interventions
MR scan
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 18 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Advanced Cancer
Interventions
Lucitanib
Drug
Lead sponsor
Teresa Helsten, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
La Jolla, California
Not yet recruiting No phase listed Observational

Cranial Remolding Orthosis Registry

NCT06762691
Conditions
Plagiocephaly, Brachycephaly, Asymmetric Head
Interventions
MyCRO Band, Traditional CRO
Device
Lead sponsor
Otto Bock HealthCare LP
Industry
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Madison Heights, Michigan
Completed Not applicable Interventional Results available

Bedside Resources to Gauge Intravascular Volume Status

NCT03915587
Conditions
Hypovolemia, Craniosynostoses
Interventions
CardioQ-EDM and CipherOx-CRI
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
3 Months to 2 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Completed No phase listed Observational

Child and Infant Learning Project

NCT00077831
Conditions
Craniosynostosis
Interventions
neurobehavioral development
Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
2 Months to 7 Years
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
4
States / cities
Atlanta, Georgia • Westchester, Illinois • St Louis, Missouri + 1 more
Conditions
Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Interventions
Pemigatinib, Pembrolizumab, Gemcitabine, Carboplatin
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
13
States / cities
Greenbrae, California • Newark, Delaware • Marietta, Georgia + 10 more
Conditions
Urothelial Cancer, Receptors, Fibroblast Growth Factor
Interventions
Archival Tumor Tissue Sample
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
3,679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Tucson, Arizona • Denver, Colorado • Newark, Delaware + 20 more
Conditions
Craniosynostosis, Sagittal
Interventions
Endoscopic strip craniectomy (with lateral osteotomies) with post-operative helmet therapy, Endoscopic strip craniectomy (without lateral osteotomies) with post-operative helmet therapy
Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 6 Months
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Craniosynostosis
Interventions
Epsilon-Aminocaproic Acid
Drug
Lead sponsor
Paul Stricker
Other
Eligibility
2 Months to 24 Months
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Craniosynostosis, Philadelphia Type Craniosynostosis
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Cancer
Interventions
Lenvatinib
Drug
Lead sponsor
Teresa Helsten, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
La Jolla, California • Chicago, Illinois
Conditions
Craniofacial Differences
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
12 Years to 20 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Gastric Adenocarcinoma
Interventions
Derazantinib, Derazantinib-paclitaxel-ramucirumab combination
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Orlando, Florida • New York, New York
Conditions
Craniosynostosis
Interventions
high dose TXA, Low dose TXA
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
3 Months to 6 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 1Phase 2 Interventional Results available

Derazantinib and Atezolizumab in Patients With Urothelial Cancer

NCT04045613
Conditions
Urothelial Carcinoma
Interventions
Derazantinib 300 mg once daily monotherapy, Derazantinib 200 mg once daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily + atezolizumab 1200 mg, Derazantinib 200 mg twice daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily monotherapy (QD), Derazantinib 200 mg twice daily monotherapy
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Newnan, Georgia • New York, New York • Port Jefferson Station, New York + 4 more
Conditions
Hydrocephalus in Children, Epilepsy, Craniosynostoses, Traumatic Brain Injury
Interventions
McDESPOT
Device
Lead sponsor
Memorial Healthcare System
Other
Eligibility
Up to 19 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Hollywood, Florida
Conditions
Plagiocephaly, Scaphocephaly, Brachycephaly
Interventions
Cranial cup device and Moldable positioner, Moldable positioner device
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 10 Days
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Craniosynostosis
Interventions
biopsy
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
2 Months to 18 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Conditions
Metopic Craniosynostosis
Interventions
Allogenix Plus
Biological
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Months to 36 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Columbia, Missouri
Conditions
UC (Urothelial Cancer)
Interventions
pemigatinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
34
States / cities
Tucson, Arizona • San Diego, California • San Francisco, California + 31 more
Conditions
Craniosynostosis, Muenke Syndrome
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2020
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Conditions
Colorectal Cancer, Colorectal Adenocarcinoma
Interventions
Brivanib, Irinotecan
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Active, not recruiting No phase listed Observational

Pathogenetic Basis of Aortopathy and Aortic Valve Disease

NCT03440697
Conditions
Aortopathies, Thoracic Aortic Aneurysm, Aortic Valve Disease, Thoracic Aortic Disease, Thoracic Aortic Dissection, Thoracic Aortic Rupture, Ascending Aortic Disease, Descending Aortic Disease, Ascending Aortic Aneurysm, Descending Aortic Aneurysm, Marfan Syndrome, Loeys-Dietz Syndrome, Vascular Ehlers-Danlos Syndrome, Shprintzen-Goldberg Syndrome, Turner Syndrome, PHACE Syndrome, Autosomal Recessive Cutis Laxa, Congenital Contractural Arachnodactyly, Arterial Tortuosity Syndrome, Bicuspid Aortic Valve-Associated Aortopathy, Bicuspid Aortic Valve, Familial Thoracic Aortic Aneurysm and Aortic Dissection
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2030
U.S. locations
2
States / cities
Atlanta, Georgia • Indianapolis, Indiana